GLTO

#11857
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
28.69
28.69
Range Annuel
2.01
38.33
Changement quotidien
-0.76%
Changement Mensuel
-6.00%
Evolution sur 6 mois
+917.38%
Changement Annuel
+613.68%
Clôture Précédente
28.91
Open
28.69
Bid
Ask
Low
28.69
High
28.69
Volume
10
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Nouvelles